Rejected at 7:29 a.m. Mar, 15, 2024 ] by Ahmed7
Bulk Suggestion Bulk ID: gabernathy2026/03.15.24-12:10AM
Author: gabernathy2026
Related Note: 1509449043151
Rationale for change

.

Rejection reason

Bulk rejection

Sketchy Extra Sketchy Extra
Text
What is the first-line pharmacotherapy for attention-deficit hyperactivity disorder (ADHD) ≥ 6 years old?

{{c1::Stimulants (e.g., methylphenidate, amphetamines)}}
Extra
- Non-stimulant treatment options include atomoxetine (no addiction risk!) and α2-agonists (e.g., guanfacine, clonidine)

- < 6 years old: first-line is CBT
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy



Sketchy 2
Empty field
Picmonic
Empty field
Pixorize


Review Clonidine & Guanfacine


Physeo

Bootcamp
Watch associated Bootcamp video - Developmental Disorders : ADHD
OME

Additional Resources
One by one
Empty field
#AK_Step2_v12::!Shelf::Psych::no_dupes::only_step2 #AK_Step3_v12::#UWorld::10154 #AK_Step1_v12::#Pixorize::03_Pharmacology::04_Sympathomimetics_&_Sympatholytics::10_Clonidine_(and_Guanfacine) #AK_Original_Decks::Step_2::Cheesy_Dorian_(M3) #PANCE::EOR::PEDS #AK_Step2_v12::#Resources_by_rotation::Psych::uworld::dorian #AK_Step1_v12::#OME::Clinical::Pediatrics/Psychiatry::Pediatric_Psychiatry::Neurodevelopmental_Disorders #AK_Step1_v12::#NBME::31 #AK_Step2_v12::#UWorld::Step::15854 #AK_Step3_v12::#UWorld::10035 #PANCE::BEHAVIORAL::ADHD #AK_Step2_v12::#Subjects::Psychiatry::12_Childhood_&_Early_Onset_Disorders::ADHD::Management #AK_Step2_v12::Original_decks::Zanki_Step_2::Psych::UW_Psych #AK_Step2_v12::#SketchyPsych::07_Child_&_Adolescent_Psychiatry::02_ADHD::01_ADHD #AK_Step1_v12::#Bootcamp::Psychiatry::02_Developmental_Disorders::01_ADHD !AK_UpdateTags::Step2decks::Cheesy-Dorian-(M3)::Psychiatry::3-UWorld #AK_Step2_v12::#B&B::12_Pediatrics::03_Other::03_Child_Psychiatry #AK_Step2_v12::#AMBOSS::sJ0tvS #AK_Step3_v12::#UWorld::10034 #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::07_Amphetamines_and_Methylphenidate #AK_Step1_v12::#B&B::17_Psych::02_Pathology::04_ADHD_and_Autism !AK_UpdateTags::^temporary::ImageFix::Table #AK_Step2_v12::!Shelf::Psych::no_dupes #AK_Step2_v12::Original_decks::Dorian::psych::uw #AK_Step1_v12::#NBME::21 #AK_Step2_v12::#OME::04_Psychiatry::12_Peds_Neurodevelopmental #AK_Step2_v12::#AMBOSS::as0Qth #AK_Step2_v12::#Resources_by_rotation::Psych::amboss::medicalark #AK_Step1_v12::#Pixorize::03_Pharmacology::23_Sympathomimetics_&_Sympatholytics_(New)::06_Clonidine_Guanfacine #AK_Step2_v12::#Subjects::Psychiatry::12_Childhood_&_Early_Onset_Disorders::ADHD #AK_Step2_v12::#Resources_by_rotation::Psych::uworld::zanki #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step2_v12::!Shelf::#Cards_AnKing_Did::5psych #PANCE::EOR::PSYCH #AK_Step1_v12::#NBME::18 #AK_Step1_v12::#SketchyPharm::06_Neuro_&_Psych::05_Psychostimulants_Narcolepsy_ADHD::02_Amphetamine_Dexamphetamine_Lisdexamfetamine_Methylphenidate #AK_Step1_v12::#AMBOSS::QA0uji #AK_Step2_v12::#AMBOSS::uJ0pDS #AK_Step1_v12::#SketchyPharm::01_Autonomic_Drugs::02_Sympathetic::02_Indirect_sympathomimetics